ExpreS2ion Biotechnologies has a broad portfolio of vaccine candidates based on its ExpreS2 platform.
Right now, the company is eagerly awaiting top-line results from the phase III study with its Covid-19 vaccine. Meanwhile the cancer vaccine candidate ES2B-C001 is advancing towards the clinic.
The company is currently raising 102 MSEK in a rights issue.
BioStock.